Phillip D. Toth

3.3k total citations · 1 hit paper
25 papers, 1.8k citations indexed

About

Phillip D. Toth is a scholar working on Surgery, Cardiology and Cardiovascular Medicine and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Phillip D. Toth has authored 25 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Surgery, 9 papers in Cardiology and Cardiovascular Medicine and 4 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Phillip D. Toth's work include Lipoproteins and Cardiovascular Health (5 papers), Blood Pressure and Hypertension Studies (5 papers) and Hemodynamic Monitoring and Therapy (5 papers). Phillip D. Toth is often cited by papers focused on Lipoproteins and Cardiovascular Health (5 papers), Blood Pressure and Hypertension Studies (5 papers) and Hemodynamic Monitoring and Therapy (5 papers). Phillip D. Toth collaborates with scholars based in United States, United Kingdom and Czechia. Phillip D. Toth's co-authors include Steven K. Burke, Michael H. Davidson, Harold Bays, Stuart Weiss, Jae Bum Kim, Lesley Burgess, Eli M. Roth, Christie M. Ballantyne, Maria Laura Monsalvo and Evan A. Stein and has published in prestigious journals such as New England Journal of Medicine, Critical Care Medicine and The Journal of Urology.

In The Last Decade

Phillip D. Toth

25 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

2014 553 citations Dirk Blom, Tomas Hala et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Phillip D. Toth United States	11	1.3k	586	382	254	231	25	1.8k
A.F.H. Stalenhoef Netherlands	21	1.2k 1.0×	777 1.3×	142 0.4×	380 1.5×	590 2.6×	44	2.2k
Jonathan L. Isaacsohn United States	22	1.5k 1.2×	725 1.2×	266 0.7×	289 1.1×	582 2.5×	50	2.4k
Barry Gumbiner United States	25	1.3k 1.0×	1.1k 2.0×	301 0.8×	356 1.4×	266 1.2×	51	2.7k
Teik Chye Ooi Canada	27	1.2k 0.9×	1.0k 1.7×	189 0.5×	309 1.2×	633 2.7×	79	2.4k
Fergus McTaggart United Kingdom	18	981 0.8×	376 0.6×	245 0.6×	365 1.4×	165 0.7×	33	1.6k
Amy O. Johnson‐Levonas United States	28	1.3k 1.0×	801 1.4×	333 0.9×	416 1.6×	344 1.5×	89	2.4k
Greg Brown United States	3	1.3k 1.0×	755 1.3×	162 0.4×	264 1.0×	573 2.5×	3	1.8k
Matilda Florentin Greece	24	719 0.6×	584 1.0×	92 0.2×	161 0.6×	274 1.2×	73	1.7k
Michael S. Kostapanos Greece	25	1.1k 0.9×	801 1.4×	161 0.4×	314 1.2×	491 2.1×	79	2.5k
Tatu Miettinen Finland	15	924 0.7×	429 0.7×	190 0.5×	236 0.9×	180 0.8×	24	1.4k

Countries citing papers authored by Phillip D. Toth

Since Specialization

Citations

This map shows the geographic impact of Phillip D. Toth's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip D. Toth with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip D. Toth more than expected).

Fields of papers citing papers by Phillip D. Toth

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phillip D. Toth. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip D. Toth. The network helps show where Phillip D. Toth may publish in the future.

Co-authorship network of co-authors of Phillip D. Toth

This figure shows the co-authorship network connecting the top 25 collaborators of Phillip D. Toth. A scholar is included among the top collaborators of Phillip D. Toth based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phillip D. Toth. Phillip D. Toth is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Blom, Dirk, Tomas Hala, Michael A. Bolognese, et al.. (2014). A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. New England Journal of Medicine. 370(19). 1809–1819. 553 indexed citations breakdown →

Maki, Kevin C., Leslie L. Curry, Matthew S. Reeves, et al.. (2008). Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology. 46(7). S47–S53. 121 indexed citations

Maki, Kevin C., Leslie L. Curry, M. C. Carakostas, et al.. (2008). The hemodynamic effects of rebaudioside A in healthy adults with normal and low-normal blood pressure. Food and Chemical Toxicology. 46(7). S40–S46. 54 indexed citations

Sramek, John J., Mark Leibowitz, Samuel Weinstein, et al.. (2002). Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Journal of Human Hypertension. 16(1). 13–19. 43 indexed citations

Kashyap, Moti L., Mark E. McGovern, Kathleen Berra, et al.. (2002). Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia**A complete list of participants in the Research Group and Publication Committee appears in the Appendix.. The American Journal of Cardiology. 89(6). 672–678. 182 indexed citations

Davidson, Michael H., Phillip D. Toth, Stuart Weiss, et al.. (2001). Low‐dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low‐density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clinical Cardiology. 24(6). 467–474. 81 indexed citations

Insull, William, Phillip D. Toth, William S. Mullican, et al.. (2001). Effectiveness of Colesevelam Hydrochloride in Decreasing LDL Cholesterol in Patients With Primary Hypercholesterolemia: A 24-Week Randomized Controlled Trial. Mayo Clinic Proceedings. 76(10). 971–982. 109 indexed citations

Bays, Harold, Paul B. Moore, Margaret Drehobl, et al.. (2001). Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clinical Therapeutics. 23(8). 1209–1230. 253 indexed citations

Davidson, Michael H., Maureen Dillon, Bruce R. Gordon, et al.. (1999). Colesevelam Hydrochloride (Cholestagel). Archives of Internal Medicine. 159(16). 1893–1893. 245 indexed citations

10.

Overstreet, James W., Vivian L. Fuh, John E. Gould, et al.. (1999). CHRONIC TREATMENT WITH FINASTERIDE DAILY DOES NOT AFFECT SPERMATOGENESIS OR SEMEN PRODUCTION IN YOUNG MEN. The Journal of Urology. 1295–1300. 6 indexed citations

11.

Weidler, Donald J., Charles L. Curry, Keith C. Ferdinand, et al.. (1995). Efficacious Response with Lower Dose Indapamide Therapy in the Treatment of Elderly Patients with Mild to Moderate Hypertension. The Journal of Clinical Pharmacology. 35(1). 45–51. 10 indexed citations

12.

Weiss, Robert, et al.. (1994). CLINICAL EFFICACY AND SAFETY OF LOWER-DOSE INDAPAMIDE THERAPY IN THE TREATMENT OF PATIENTS WITH MILD TO MODERATE HYPERTENSION. American Journal of Therapeutics. 1(1). 58–64. 5 indexed citations

13.

Toth, Phillip D., et al.. (1993). Use of noninvasive bioelectric impedance to predict cardiac output in open heart recovery. Biological Psychology. 36(1-2). 23–32. 2 indexed citations

14.

Bizzini, B, et al.. (1988). Defining a recion on tetanus toxin responsible for neuromuscular blockade. Toxicon. 26(3). 309–318. 6 indexed citations

15.

Toth, Phillip D., et al.. (1988). Comparison of the effects of pindolol and atenolol on hemodynamic function in systemic hypertension. The American Journal of Cardiology. 62(7). 413–418. 6 indexed citations

16.

Hamburger, Steven A., et al.. (1988). Noninvasive Measurement of Systolic Time Intervals in the DogThrough the Use of Bioelectric Impedance. American Journal of Noninvasive Cardiology. 2(1-2). 119–124. 1 indexed citations

17.

Toth, Phillip D., et al.. (1988). The Use of Noninvasive Bioelectric Impedance to Determine CardiacOutput: Factors Affecting Its Accuracy. American Journal of Noninvasive Cardiology. 2(1-2). 112–118. 8 indexed citations

18.

Toth, Phillip D., et al.. (1986). [Comparative evaluation of carticaine and bupivacaine in epidural anesthesia in cesarean section].. PubMed. 108(12). 739–43. 2 indexed citations

19.

Toth, Phillip D., et al.. (1986). THE EFFECTS OF A PLATELET-ACTIVATING FACTOR ANTAGONIST (CV-3988) ON ENDOTOXIC AND HEMORRHAGIC SHOCK IN DOGS. Critical Care Medicine. 14(4). 413–413. 2 indexed citations

20.

Judy, William V., et al.. (1986). FLUID CHALLENGE ASSESSMENT BY BIOELECTRIC IMPEDANCE. Critical Care Medicine. 14(4). 379–379. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact